Reuters logo
Ophthotech licenses experimental eye drug to Novartis
May 19, 2014 / 8:21 PM / 4 years ago

Ophthotech licenses experimental eye drug to Novartis

May 19 (Reuters) - Ophthotech Corp said it granted the rights to market its experimental eye drug outside the United States to a unit of Novartis AG.

Ophthotech said it could receive immediate payments including upfront fees of $200 million and milestone payments of $130 million.

The company said it could receive over $1 billion in upfront and milestone payments over the course of the collaboration, not including royalties on potential sales of the drug, Fovista. (Reporting By Vrinda Manocha in Bangalore; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below